3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
27
Prostatic Neoplasms
12
Leukemia
12
Lymphoma
7
Burkitt Lymphoma
7
Leukemia, Biphenotypic, Acute
6
Lymphoma, Large B-Cell, Diffuse
5
Recurrence
4
Lymphoma, Non-Hodgkin
4
Pituitary Neoplasms
3
Lymphoma, Large-Cell, Immunoblastic
3
Lymphoma, B-Cell
3
Leukemia, Myeloid, Acute
3
Hodgkin Disease
3
Rhabdoid Tumor
2
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
2
Polycystic Ovary Syndrome
2
Obesity
2
Neoplasms
2
Multiple Myeloma
2
Lymphoma, T-Cell
2
Lymphoma, Mantle-Cell
2
Lymphoma, Large-Cell, Anaplastic
2
Lymphoma, Follicular
2
Hematologic Neoplasms
2
Radiodermatitis
1
Pyloric Stenosis, Hypertrophic
1
Plasmablastic Lymphoma
1
Pituitary Diseases
1
Pinealoma
1
Interventions
Carboplatin
177
Radiotherapy
139
Cisplatin
110
Pemetrexed
102
Docetaxel
93
Paclitaxel
92
Gemcitabine
78
Erlotinib Hydrochloride
73
Magnetic Resonance Spectroscopy
72
Radiosurgery
67
Bevacizumab
65
pembrolizumab
64
Etoposide
60
Blood Specimen Collection
60
durvalumab
53
Specimen Handling
48
Nivolumab
48
Surveys and Questionnaires
47
Drug Therapy
41
Standard of Care
35
Radiation
33
osimertinib
32
atezolizumab
32
Surgical Procedures, Operative
30
Topotecan
29
Irinotecan
29
Gefitinib
29
Educational Status
29
Early Intervention, Educational
29
Biopsy
28
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Lung Neoplasms
×
Hydrocortisone
×
Clear all
NCT00473083
2017-04-04
LUTRAERL
British Columbia Cancer Agency
Phase 2
Completed
150 enrolled
13 charts